Main > A1. CORP. INDEX. G-Gm > Genmab/P C2
Genmab/P C2's subsections
2006. 12.19.2006. GlaxoSmithKline
2007. 08.02.2007. Merck Serono
2007. 09.07.2007. Onco.>Anti CD20
2007. 09.13.2007. Dermatology
2007. 09.13.2007. Onco.>Anti EGFr
2007. 09.13.2007. Onco.>Anti IL-8
2007. 09.13.2007. Pneumology
2007. 09.27.2007. Onco.>Anti CD20
2007. 10.02.2007. Roche CTA 3rd. Ab
2007. 10.11.2007. Onco.
2007. 12.11.2007. Roche 4th Ab
2007. 12.13.2007. Neurology >
2007. 12.14.2007. Onco.>Anti CD20
2008. 01.04.2008. Onco.>Anti CD32b
2008. 01.21.2007. Onco.>Anti CD20
2008. 03.13.2008. Ab Plant Acq.
2008. 06.10.2008. RA>Anti CD20
2008. 09.23.2008. Onco.>Anti CD20
2009. 12.04.2009. Onco.>RG1507
2010. 09.14.2010. Seattle Genetics
2011. 04.19.2011. Seattle Genetics
2012. 02.10.2012. Lundbeck
2012. 03.19.2012. Onco.>Anti CD20
2012. 03.26.2012. Patent Settlement
2012. 06.04.2012. Novartis
2013. 03.25.2013. Onco.>Anti CD20
2013. 05.01. Onco.>CLL>O+B
2013. 09.13. Onco.>CLL>O+C
2013. 10.10. Neuro.>MS
2013. 11.26. Janssen Biotech
2014. 03.26. Onco.>MM
2014. 07.31. Onco.>CLL>O
2015. 11.16. Onco.>MM
2021. 06.22. Hemato.>AL Amyloidosis
2021. 09.20. Onco.>Cervical C.
2023. 09.25. EU Approval
2023. 09.25. JP Approval
2024. 04.03. Acq. ProfoundBio
Patents
Web-Site
Z - OK
Genmab/P C2's products
This section has no products